Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes

Sophie Dimicoli1*, Yue Wei1*, Carlos Bueso-Ramos2, Hui Yang1, Courtney DiNardo1, Yu Jia1, Hong Zheng1, Zhihong Fang1, Martin Nguyen2, Sherry Pierce1, Rui Chen3, Hui Wang3, Chenghua Wu3, Guillermo García-Manero1*

1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 2 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 3 Department of Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America

Abstract

MYD88 is a key mediator of Toll-like receptor innate immunity signaling. Oncogenically active MYD88 mutations have recently been reported in lymphoid malignancies, but has not been described in MDS. To characterize MYD88 in MDS, we sequenced the coding region of the MYD88 gene in 40 MDS patients. No MYD88 mutation was detected. We next characterized MYD88 expression in bone marrow CD34+ cells (N = 64). Increased MYD88 RNA was detected in 40% of patients. Patients with higher MYD88 expression in CD34+ cells had a tendency for shorter survival compared to the ones with lower MYD88, which was significant when controlled for IPSS and age. We then evaluated effect of MYD88 blockade in the CD34+ cells of patients with lower-risk MDS. Colony formation assays indicated that MYD88 blockade using a MYD88 inhibitor resulted in increased erythroid colony formation. MYD88 blockade also negatively regulated the secretion of interleukin-8. Treatment of MDS CD34+ cells with an IL-8 antibody also increased formation of erythroid colonies. These results indicate that MYD88 plays a role in the pathobiology of MDS and may have prognostic and therapeutic value in the management of patients with this disease.

Introduction

The myelodysplastic syndromes (MDS) are a complex group of myeloid disorders characterized by peripheral blood cytopenias, ineffective bone marrow hematopoiesis, and increased propensity of transformation to acute myelogenous leukemia (AML) [1]. Recent use of advanced DNA sequencing technologies has allowed the identification of multiple genetic lesions in MDS [2]. Despite these advances, the molecular pathogenesis of MDS remains unclear. The innate immunity system is well known as a conserved host defence mechanism that detects and eliminates pathogens [3]. Activation of innate immune signaling pathways can be initiated through the stimulation of pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs) [4], with conserved molecular patterns of microorganisms. These signals are mediated via downstream signaling mediators and eventually lead to activation of key intracellular molecular effectors such as NF-kB and MAPK. The resulting immune responses, including release of inflammatory cytokines, cause elimination of pathogens. Although innate immunity responses are mediated mostly by phagocytes such as macrophages and dendritic cells, emerging evidence has suggested that innate immune signalling activation can also directly impact hematopoietic stem and early progenitor cells (HSPCs) [5,6] and may be involved in the pathogenesis of MDS [7]. For instance, mir-145 and 146a are two microRNAs that have been shown to target the innate immune signal adaptors TIRAP and TRAF6 respectively [7]. Loss of these two microRNAs is involved in the 5q- syndrome subtype of MDS and overexpression of TIRAP and TRAF6 is associated with transformation to acute leukemia or marrow failure in a murine transplant system [8]. TIRAP and TRAF6 are both known to mediate MYD88 (Myeloid differentiation gene 88) dependent innate immune signals [4]. MYD88 mediated signalling is common to all Toll-like Receptors (TLR) except for the TLR3 pathway [9]. Of importance, oncogenically active MYD88 mutations have recently been identified as recurrent genetic lesions in chronic lymphocytic leukemia (CLL), B-cell lymphoma and Waldenstrom’s macroglobulinemia [10–12]. To evaluate if MYD88 also plays a pathological role in myeloid...
neoplasia, we studied MYD88 in primary samples of patients with MDS, including MYD88 mutation analysis in bone marrow mononuclear cells and the characterization of MYD88 RNA expression in bone marrow CD34+ cells and also investigated the impact of MYD88 blockade and downstream inflammatory interleukin IL-8 [13] in primary MDS CD34+ cells cultured in vitro.

Materials and Methods

MYD88 Gene Pyrosequencing Analysis

Pyrosequencing analysis was performed in 38 patients with MDS. Exons 3 and 4 of MYD88 were amplified by polymerase chain reaction using primers listed on Table S1. These primers were chosen based on published data [10–12]. For pyrosequencing assay, the reverse primer was biotinylated. This biotinylated strand was captured on streptavidin sepharose beads (Amersham Biosciences, Uppsala, Sweden) and annealed with a sequencing primer. Pyrosequencing was performed using PSQ HS 96 Gold SNP reagents and the PSQ HS 96 pyrosequencing machine (Biotage, Uppsala, Sweden). Programmed polymorphic sites were set at specific nucleotides (see table below) to detect any mutations. Mutations were detected as abnormal program patterns (pyrosequencing peak).

MYD88 Gene Barcode PCR-deep Sequencing Analysis

The complete coding region of MYD88 gene was amplified using ten pairs of PCR primers in 40 patients with MDS (38 described above and two additional ones). Characteristics of these patients are listed in Table 1. First round PCR products were then amplified in 2nd round PCR using universal primers with Illumina adaptor and 40 patient-specific barcode sequences. All PCR products were then pooled together and sequenced using the Illumina HiSeq 2000 (Illumina, San Diego CA). All PCR primers are listed in Table S2. MYD88 sequencing dataset can be accessed at NIH Short Read Archive using ID SRP026064.

Real-Time RT-PCR

Total cellular RNA was extracted using Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. For each sample, 200 ng of total RNA were used for reverse transcription (RT) reactions using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA) following the manufacturer’s protocol. For real-time PCR, primers and probes were purchased from Applied Biosystems and analyzed using an Applied Biosystems Prism 7500 Sequence Detection System. PCR reactions were performed using 20×Assays-On-Demand Gene Expression Assay Mix and TaqMan Universal PCR Master mix according to the manufacturer’s protocol. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control. Quantitative values were obtained from the cycle number (Ct value), at which an increase in fluorescent signal associated with an exponential accumulation of PCR products was detected. The amount of target gene was normalized to the endogenous reference GAPDH to obtain the relative threshold cycle (ΔCt) and then related to the Ct of the control to obtain the relative expression level (2−ΔΔCt) of target gene.

Cell Lines and Reagents

KG1 cells were obtained from ATCC (Manassas, VA) and were cultured in IMDM, 20% fetal calf serum and 1% penicillin-streptomycin. TLR-agonists MALP2 (2 μg/ml) and PAM3CSK4 (0.1 μg/ml) were purchased from Invivogen (San Diego, CA). MYD88 peptide inhibitor (Pepinh-MYD) or peptide control

| Table 1. Clinical Characteristics of Patients in MYD88 Mutation Analysis. |
|---------------------------------|-------------|-------|
| Characteristics (N = 40)        | No. of Patients | %    |
| Age, years                      | Median 68     |       |
| Range                           | 28–84         |       |
| Sex                             | Male 24       | 60    |
|                                 | Female 16     | 40    |
| BM blast, %                     | Median 5      |       |
|                                 | Range 0–33    |       |
| WBC, ×10^3/μL                   | Median 3      |       |
|                                 | Range 0.8–116.1|     |
| Hemoglobin, g/dL                | Median 10     |       |
|                                 | Range 6.8–15  |       |
| Platelet, ×10^3/μL              | Median 95     |       |
|                                 | Range 1–488   |       |
| Neutrophil, ×10^3/μL            | Median 52     |       |
|                                 | Range 0–85    |       |
| Prior Malignancy                 | Yes 11        | 27.5  |
|                                 | No 29         | 72.5  |
| Prior Chemotherapy               | Yes 6         | 15    |
|                                 | No 34         | 85    |
| Prior Radiotherapy               | Yes 2         | 5     |
|                                 | No 38         | 95    |
| Dx                              | RARS/RCMD/RCMD-Rs 8 | 20 |
|                                 | RAEB 13  | 32.5  |
|                                 | CMML 3      | 7.5   |
|                                 | AML/AMML 5  | 12.5  |
|                                 | MPD 3      | 7.5   |
|                                 | other 8     | 20    |
| IPSS                            | H 4         | 15    |
|                                 | I-2 9       | 35    |
|                                 | I-1 10      | 38    |
|                                 | L 3         | 12    |
|                                 | NA 14        |       |
| Cytogenetics                    | Dip 23       | 57.5  |
|                                 | 5q+ 3        | 7.5   |
|                                 | other 11     | 27.5  |
|                                 | IM 3        | 7.5   |

doi:10.1371/journal.pone.0071120.t001
NF-κB Activity Evaluation by Luciferase Assay

KG1 cells were transfected with pGL3.32[luc2P/NF-κB-RE] (Promega, Madison, WI) using the Nucleofector Device and Nucleofector T kit (Lonza, Basel, Switzerland). These cells were pre-treated with 5 μM MYD88 peptide inhibitor or peptide control (Invivogen, San Diego, CA). pRL-TK Vectors expressing the Renilla luciferase was also cotransfected as internal control. One day after transfection, TLR2 agonist MALP2 (2 μg/ml) or PAM3CSK4 (0.1 μg/ml) (Invivogen, San Diego, CA) was added into medium. Luciferase assays were performed 20 hours later with the Dual-Luciferase Reporter Assay kit (Promega, Madison, WI) on 3010 luminometer (BD Biosciences, San Diego, CA). NF-κB activity was calculated by the ratio of firefly luminescence from the pGL4.32[luc2P/NF-κB-RE] reporter to the renilla luminescence from the control pRL-TK Vectors reporter.

ELISA

IL-8 protein level in bone marrow plasma and in culture medium was analyzed using Human CXCL8/IL-8 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN).

Statistical Methods

Descriptive statistics were used for baseline characteristics. Non-parametric analyses were used; binary variables were compared using the Fisher’s exact test, the Kruskall-Wallis test was used for categorical variables, and continuous variables by the Wilcoxon rank sum test. MYD88 levels were evaluated as a continuous and categorical/dichotomous variable, using expression levels at the 25th, 50th and 75th percentiles. Associations were considered of potential interest if the p-value was less than 0.10. Overall survival (OS) was defined from the date of sample acquisition to date of death.
death or date of last follow-up (censored). Kaplan-Meier analysis was used to construct OS curves; curves were compared by log-rank test. An adjusted Cox proportional hazards model was constructed using clinically important variables to examine the effect of potential confounders. We have updated this in the methods section.

### Results

#### Absence of Genetic Mutations in the Coding Region of MYD88 Gene in 40 Patients with MDS

Mutations of MYD88 have been identified in CLL [10], B cell lymphoma [11,12] and Waldenström’s macroglobulinemia12, which affect several conserved amino acids in the intracellular Toll/Interleukin-1 receptor (TIR) domain (Figure 1A). We first examined these previously described “hot spots” of MYD88 in MDS using pyrosequencing approach. Pyrosequencing was performed in whole bone marrow mononuclear cells isolated from 38 patients of MDS. Characteristics of these patients are described in Table 1. Sequenced codons include: V217, W218, S219, I220, S222, M232, S243, L265, and T294. Using this technique, no mutation was detected in any of the 38 MDS samples analyzed. We then expanded the sequencing efforts by using an approach that combines bar-code PCR amplification and Illumina parallel sequencing (Figure 1B). Characteristics of these patients are listed in Table 1. Eleven of these patients had prior malignancies, including one with prior Burkitt’s lymphoma in remission. The entire coding region of MYD88 of 40 MDS samples, including the 38 samples used in pyrosequencing, were amplified and sequenced. No genetic mutation of MYD88 was detected in these 40 patients with this approach either.

#### MYD88 is Overexpressed in Bone Marrow CD34+ Cells of MDS

We examined RNA expression levels of MYD88 in bone marrow CD34+ cells of patients with MDS. Analysis was performed in a cohort of 64 patients (Table 2). Characteristics of these patients are described in Table 2. Eighteen of these samples were also used for the sequencing analysis of MYD88 described earlier. We compared their MYD88 expression to 7 control normal CD34+ samples. Quantitative RT-PCR indicated that 27% of MDS patients (N = 17) had a more than 2 fold increase of MYD88 RNA, and 14% (N = 9) had a 1.3–1.9 fold increase. In total 41% (N = 26) of patients overexpress MYD88 (Figure 2A). Among these 64 patients, 35 patients (54%) were previously untreated MDS and the other 29 (45%) patients had received prior MDS treatments at the point of sample collection. Both untreated and treated patients showed increased MYD88 expression compared to controls (Figure S1A). We also analyzed MYD88 expression in these 64 patients based on their IPSS scores. MYD88 is overexpressed in patients with lower-risk (low-risk and INT-1) MDS compared to higher-risk (INT-2 and high-risk) group (p = 0.1) (Figure S1B).

#### MYD88 Expression and Patient Survival in MDS

We next evaluated correlations between MYD88 expression and patient characteristics in 62 of the 64 samples with available complete clinical information. Patients with higher MYD88 RNA expression in bone marrow CD34+ cells (split by median value) had a propensity for shorter survival (p = .09, HR 1.9, 95% CI 0.89–4.26) (Figure 2B). Of interest, higher MYD88 expression correlated significantly with shorter overall survival in the multivariate model adjusted for IPSS risk score and patient age (p = .027, HR 2.46, 95% CI 1.1–5.45). These results suggest that MYD88 expression level may hold potential prognostic value in MDS, independent of known prognostic risk factors.
Blockade of MYD88 in MDS CD34+ Cells

To study the role of MYD88 signaling in MDS, we used a 26-amino acid inhibitory peptide that blocks MYD88 homodimerization [14] [15]. Due to the lack of representative MDS cell lines, we first used KG1 cells, a CD34 positive cell line derived from AML [16] [17], to examine the effect of the MYD88 peptide inhibitor. RNA levels of MYD88 are higher in KG1 cells than in 293T cell and several other leukemia cell lines such as K-562, HL-60 or U937 (data not shown). PAM3CSK4 and MALP2 are two TLR2 agonists that increase NF-kB activity in a MYD88 dependent fashion [18], [19]. These two compounds increased NF-kB promoted luciferase activity in KG1 (Figure S2). When cells were pre-incubated with the MYD88 peptide inhibitor prior to the addition of TLR2 agonists, NF-kB activation was largely reduced (Figure 3A). This result indicates that the MYD88 peptide inhibitor can block efficiently the TLR2-MYD88 dependent downstream signals.

We next applied MYD88 inhibitor on the primary bone marrow CD34+ cells isolated from patients with lower-risk MDS (IPSS low or intermediate-1) (N = 7). Patient characteristics are described in Table S3. After two weeks of culture in methylcellulose supported erythroid and myeloid differentiation medium, and in comparison to peptide control, treatment with MYD88 inhibitor resulted in increase of the number of erythroid colonies (CFU-E) in 5 of the 7 samples (Figure 3B). In average, MYD88 inhibition led to a 2 fold increase of the numbers of erythroid colonies (Figure 3C) without an obvious effect on the numbers of myeloid colonies. The impact of MYD88 blockade on differentiation of erythroid lineage in lower-risk MDS samples was further evaluated by examining the expression of genes known to be activated during erythroid differentiation. MYD88 inhibitor treatment resulted in increased expression of CD71, EPOR, GYPA and GYPB (Figure 3D) [20] [21]. We next examined expression of GATA1 and GATA2 genes, two crucial regulators of hematopoietic differentiation, whose ratio of expression (GATA1/ GATA2) has been described to positively correlate with erythroid differentiation [22] [23] [24]. We observed that while expression of both genes increased with MYD88 blockade, the increase of GATA1 was significantly higher than GATA2 (Figure 3E), leading to an increased ratio of GATA1/GATA2 (Figure 3E). These results further support the positive effect on erythroid differentiation by MYD88 blockade in low-risk MDS CD34+ cells. We also characterized effect of MYD88 blockade on the growth of MDS CD34+ cells in another three samples that were cultured in liquid hematopoietic progenitor cell expansion medium. No obvious impact on cell growth was observed (Figure S2). We next examined the effect of MYD88 inhibitor on the hematopoietic colony formation capacity of the CD34+ cells isolated from patients with clinically classified high-risk MDS (N = 5). In contrast to the observations in low-risk samples, no positive impact on erythroid colony formation was observed in any of the three high-risk samples.

Blockade of IL-8 in MDS CD34+ Cells

Interleukin-8 (IL-8) is a key inflammatory cytokine dependent on MYD88 [25]. IL-8 has been shown to be one of the most significantly overexpressed cytokines in MDS BM CD34+ cells [26]. We analyzed IL-8 protein levels in the bone marrow plasma samples of patients with MDS (N = 33) and observed that IL-8 concentration was elevated in comparison to control counterparts (P = 0.03) (Figure 4A). We then examined IL-8 expression in the above described seven lower-risk MDS CD34+ samples treated with the MYD88 inhibitor. Treatment with MYD88 inhibitor resulted in a decrease of IL-8 RNA by 20% (Figure 4B). We next used ELISA to examine the IL-8 protein concentration in the supernatant of culture medium of MDS CD34+ cells (N = 4) treated with MYD88 inhibitor or control peptide. With the addition of MYD88 inhibitor, IL-8 protein concentration in culture medium was reduced by 30%, ranging between 16% to 40% in 4 samples (Figure 4C). These results suggest that MYD88 blockade negatively regulates the expression and secretion of IL-8 in MDS CD34+ cells. We then examined the effect of direct IL-8 blockade in MDS CD34+ cells by applying an IL-8 specific neutralization antibody in cells from patients with low-risk MDS (N = 5) (Table S4). A similar effect on hematopoietic differentiation of CD34+ cells was observed with the IL-8 antibody as with the MYD88 inhibitor. Colony formation assays indicated that IL-8 antibody treatment resulted in increased numbers of erythroid colonies in 4 of the 5 cases in comparison to isotype control treatment (Figure 4D). The average increase of the number of CFU-E in all 5 samples treated with IL-8 antibody was 1.7 fold in comparison to isotype control. Consistent with the positive impact...
on the numbers of erythroid colonies, increased CD71 and EPOR RNA expressions were also observed with IL-8 antibody treated samples (Figure 4E). No obvious increase in the RNA expression of Glycophorin A or B genes was observed after treatment with IL-8 antibody (data not shown).

**Discussion**

Recently, emerging evidence has suggested a role of the TLR mediated innate immune signal in the tumorigenesis such as in gastric cancer through mechanisms independent of chronic inflammation [27]. Similar to the findings in solid tumors, deregulated innate immune signal has also been found to directly impact hematopoietic stem/early progenitor cells (HSPCs) [7] and contribute to leukemogenesis including MDS pathogenesis. [7,28] Stimulation of TLRs is known to lead to activation of intracellular pathways such as NF-kB and p38MAPK [3], which have both been documented as important molecular signals for tumorigenesis including in MDS [29,30]. We recently report that TLR2 [26], the histone demethylase JMJD3 and multiple innate immune genes that are regulated by JMJD3 are overexpressed in BM CD34+ cells of MDS [31]. Of importance, JMJD3 is a known transcriptional target of TLR signaling stimulated NF-kB activity [32].

As an important signal adaptor for the TLR signaling, MYD88 has been previously identified as a key contributor during the pathogenesis of solid tumors including ovarian and cutaneous malignancies [33,34]. More recently, genetic lesions of MYD88 have recently been found to play an important role in lymphoid neoplasms, including ABC- diffuse large B cell lymphomas, central nervous system lymphomas, Waldenstrom macroglobulinemia, and also in T lymphomas [10–12]. Of importance, biological evidence has indicated that these recurrent genetic mutations of the MYD88 gene in lymphoma, particularly the hot-spot alteration of L265P in the TIR domain, is a gain-of-function
mutation. These results implicate that MYD88 as a proto-oncogene in these lymphoid neoplasms. In this study, we were not able to detect any genetic mutation of MYD88 in bone marrow samples of MDS. In parallel to our study, the absence of L265P mutations in acute myeloid leukemia (AML), myelomonocytic leukemia, acute lymphoblastic leukemia (ALL), and multiple myeloma has been recently reported [35]. Of note, only one of the 40 patients examined for MYD88 mutation had prior history of lymphoma. This result suggests that genetic lesions of MYD88 could be specifically important for the pathogenesis of lymphoid but not myeloid neoplasms.

While no genetic lesion in the coding region of the MYD88 gene was detected in the MDS patients, we observed that RNA expression of MYD88 was abnormally increased in a substantial percentage of MDS patients in their CD34+ cells. This result is consistent with previous reports that aberrant activation of innate immune signals in MDS, including overexpression of several TLRs [36] and loss of TRAF6 targeting microRNA in the 5q- syndrome [8]. This study also suggests that MYD88 expression level was associated to the overall survival (OS) in MDS patients. The overexpression of MYD88 in MDS also suggests that although no genetic lesion has been detected in the coding regions of the gene, sequencing effort of MYD88 should also be expanded to the regulatory sequences of this gene, including promoter and potential microRNA targeting sequences that are important for its transcriptional and translational regulation. Because disease and treatment heterogeneity of patients with MDS, we performed a tentative analysis removing 21 patients with low-risk morphologies (6 refractory anemia, 12 refractory cytopenia multilineage dysplasia [RCMD], and 3 RCMD-RS [ring sideroblasts]). The differences in expression compared to control persisted (p = 0.1) but the impact on survival was lost (p = 0.4) (data not shown). However, most likely this effect is due to the decrease in sample size. That said, larger analysis of specific morphological subsets are indicated. Indeed one limitation of the study is the relative small sample size analysed. Another limitation is that the number of overlapping samples used for both MYD88 RNA and IL-8 Elisa analysis is very small, which makes it difficult to analyze correlation between MYD88 expression and IL-8 level. Both should be further evaluated in a larger cohort of patients in the future.

Another key finding of this study is that blockage of MYD88 and downstream IL8 in MDS CD34+ cells, particularly in CD34+ cells isolated from patients with lower-risk MDS (IPSS low-risk
and intermediate-1), could positively regulate differentiation of the erythroid lineage. This observation in lower-risk samples is consistent with the observation that MYD88 expression levels tended to be higher in patients with lower-risk MDS (IPSS low-risk and intermediate-1) (Figure S1B). This effect is also consistent with our prior results of JMJ3 inhibition in MDS BM CD34+ cells [31], and that inhibition of TRAF6 in both murine and human HSPCs could prompt erythroid differentiation [0] [37]. Although the underlying molecular mechanisms are still unclear, and because anemia is one of the most common cytopenias in MDS, these observations suggest that inhibiting innate immune signals may have therapeutic role in MDS.

Overall, results of this study demonstrate that MYD88, a key innate immune signal adaptor, is potentially involved in the pathogenesis of MDS. Blockade of MYD88 mediated innate immunity signalling including IL-8 could potentially improve erythropiesis. These results further support the hypothesis that deregulation of innate immune signal contributes to the development of MDS and this is at least partially through direct impact on hematopoietic stem/progenitor cells. Further dissecting the innate immune signalling and development of pharmacological intervention of this pathway may benefit patients with MDS.

Supporting Information

Figure S1 (A) MYD88 RNA expression level in untreated (N = 35) and treated (N = 29) MDS CD34+ cells compared to control (N = 12) CD34+ cells. (B) MYD88 RNA expression levels in BM CD34+ cells of different IPSS groups compared to control. (PDF)

Figure S2 Lack of effect on cell growth for MYD88 blockade in MDS CD34+ cells. (PDF)

Table S1 Primers used for MYD88 Pyrosequencing. (PDF)

Table S2 Primers used in bar-code sequencing of MYD88. (PDF)

Table S3 Characteristics of the 5 low-risk patient MDS whose CD34+ cells treated with MYD88 inhibitor peptide. (PDF)

Table S4 Characteristics of the 5 low-risk patient MDS whose CD34+ cells treated with IL-8 antibody. (PDF)

Author Contributions

Conceived and designed the experiments: SD YW CBR RC GGM. Performed the experiments: SD YW CBR HY YJ HZ ZF MN HW. Analyzed the data: CD SP SD YW RC CW GGM. Contributed reagents/materials/analysis tools: CBR MN HY. Wrote the paper: SD YW CBR CD GGM.

References


